Liabilities / Assets
58th percentile
Tied with the lowest-debt nonprofits in its peer group.
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
Liabilities / Assets
58th percentile
Tied with the lowest-debt nonprofits in its peer group.
Liabilities / Revenue
58th percentile
Tied with the lowest-debt nonprofits in its peer group.
Net Margin
31st percentile
Higher net margin than 31% of similar nonprofits.
Top Officer Pay
78th percentile
Higher top officer pay than 78% of similar nonprofits.
Top officer pay equals 0.0% of source-year revenue.
Asset Growth
33rd percentile
Faster asset growth than 33% of similar nonprofits.
Revenue Growth
60th percentile
Faster revenue growth than 60% of similar nonprofits.
Assets
Down$91,017
Down $8,391 (-8.4%) from 2021
Net Assets
Down$91,017
Down $5,223 (-5.4%) from 2021
Liabilities
Down$0
Down $3,168 (-100%) from 2021
Revenue
Up$99,906
Up $18,736 (+23%) from 2021
Expenses
Down$105,129
Down $2,854 (-2.6%) from 2021
Net Income
Up-$5,223
Up $21,590 (+81%) from 2021
The mission of sara's cure is to make clear cell sarcoma survivable through education and scientific research while ensuring all patients and caregivers impacted have a voice and platform to enact change and strive toward the cure.
The mission of sara's cure is to make clear cell sarcoma survivable through education and scientific research while ensuring all patients and caregivers impacted have a voice and platform to enact change and strive towards the cure.
| Description | Grants | Expenses |
|---|---|---|
| SARA'S CURE IS THE ONLY NON-PROFIT REPRESENTING CLEAR CELL SARCOMA IN THE USA BUT WE COLLABORATE WITH OTHERS THROUGHOUT THE WORLD TO ENSURE OUR WORK IS EFFICIENT, MEANINGFUL AND IMPACTFUL TO THE CCS FAMILY OF PATIENTS AND OUR CHAMPION CLINICIANS. THROUGHOUT 2021 WE HAVE CONTINUED FUNDING REPURPOSED DRUG TESTING BY WORKING WITH OUR MEDICAL ADVISORS AND THEIR LABS. OUR EXECUTIVE DIRECTOR SERVES ON AN FDA REPURPOSED DRUG TESTING TASK FORCE THAT MEETS MONTHLY. THIS STRATEGIC INVOLVEMENT WITH KEY LEADERS ENSURES THAT THE TIME AND MONEY SPENT IS PUT TO ITS HIGHEST AND BEST USE. IN NOVEMBER 2021 THE FIRST OF ITS KIND PHASE I/II CCS TRIAL OPENED. THIS WAS DONE IN COLLABORATION WITH RAFAEL (NOW CORNERSTONE PHARMA), THE FDA, AND MOST IMPORTANT THE CCS FAMILY OF PATIENTS. WE PARTNERED TO DO THIS BY AGREEING TO PROVIDE FINANCIAL SUPPORT TO PATIENTS IN THE FORM OF TRAVEL REIMBURSEMENT TO HELP PATIENTS GET TO TRIAL LOCATIONS. WE HIRED THE NATIONAL ORGANIZATION OF RARE DISORDERS TO MANAGE THE DISBURSEMENT OF FUNDS TO THE CCS PATIENTS DIRECTLY. WE HAVE HELPED SEVERAL PATIENTS TO DATE. THE CLINICAL TRIAL IS ONGOING. WE CONTINUE TO BUILD THE REGISTRY WITH NORD AND FINALIZED THE DATA DICTIONARY IN DEC 2021. WE CONTINUE TO SUPPORT PATIENTS THROUGH REFERRALS TO SARCOMA CENTERS OF EXCELLENCE AND TO THE DOCTORS THAT CHAMPION THE CCS RESEARCH WHO WORK WITH US TO SUPPORT OUR MISSION. WE ATTENDED THE WORLD ORPHAN DRUG CONGRESS IN AUGUST 2021 AND HAD A CCS FATHER/BOARD MEMBER ATTEND AS WELL AS OUR EXECUTIVE AND SCIENTIFIC DIRECTORS WHO ALSO ATTENDED THE NORD AND CTOS SARCOMA CONFERENCES VIRTUALLY. THE CCS FAMILY OF PATIENTS CONTINUES TO BE THE DRIVING FORCE WITHIN THE ORGANIZATION AND HAS BEEN CRITICAL TO ACTIVELY AND FINANCIALLY SUPPORTING THE WORK WE DO BY PARTICIPATING IN FOCUS GROUPS, PROVIDING PATIENT EXPERIENCE INPUT AND HOSTING FUNDRAISERS IN THEIR COMMUNITIES AROUND THE GLOBE INCLUDING ONLINE EVENTS AND FACEBOOK FUNDRAISERS. | - | - |
| Name | Title | Full / Part Time | Base | Other | Total |
|---|---|---|---|---|---|
| LENNIE WOODS | Executive Di | - | $0 | - | - |
| KELLY ARGRAVES PHD | Scientific D | - | $0 | - | - |
| JENAE HELLER | Board Member | - | $0 | - | - |
| DRU WILLIAMS | Board Member | - | $0 | - | - |
| DAWN JUDD | Treasurer | - | $0 | - | - |
| DENNY WOODS | Board Member | - | $0 | - | - |
| BRUCE NEWBY | Board Member | - | $0 | - | - |
| NANETTE DETURK | Board Member | - | $0 | - | - |
| EVAN BARNES | Board Member | - | $0 | - | - |
| Event | Gross Receipts | Gross Revenue | Direct Expenses | Net Income |
|---|---|---|---|---|
| Special Events | $16,693 | $16,693 | - | $16,693 |
| Total Events | $16,693 | $16,693 | - | $16,693 |
“Special events other expenses 17,915 taxes/licenses 80 islands against cancer 7,551 expenses advertising and website 11,794 marketing materials 4,239 bank & credit card fees 66 supplies 1,023 travel 22,172 other expenses 104 total 64,944”
“CREDIT CARD 3,168 0”
“The mission of sara's cure is to make clear cell sarcoma survivable through education and scientific research while ensuring all patients and caregivers impacted have a voice and platform to enact change and strive towards the cure.”
“Sara's cure is the only non-profit representing clear cell sarcoma in the usa but we collaborate with others throughout the world to ensure our work is efficient, meaningful and impactful to the ccs family of patients and our champion clinicians. Throughout 2021 we have continued funding repurposed drug testing by working with our medical advisors and their labs. Our executive director serves on an fda repurposed drug testing task force that meets monthly. This strategic involvement with key leaders ensures that the time and money spent is put to its highest and best use. In november 2021 the first of its kind phase i/ii ccs trial opened. This was done in collaboration with rafael (now cornerstone pharma), the fda, and most important the ccs family of patients. We partnered to do this by agreeing to provide financial support to patients in the form of travel reimbursement to help patients get to trial locations. We hired the national organization of rare disorders to manage the disbursement of funds to the ccs patients directly. We have helped several patients to date. The clinical trial is ongoing. We continue to build the registry with nord and finalized the data dictionary in dec 2021. We continue to support patients through referrals to sarcoma centers of excellence and to the doctors that champion the ccs research who work with us to support our mission. We attended the world orphan drug congress in august 2021 and had a ccs father/board member attend as well as our executive and scientific directors who also attended the nord and ctos sarcoma conferences virtually. The ccs family of patients continues to be the driving force within the organization and has been critical to actively and financially supporting the work we do by participating in focus groups, providing patient experience input and hosting fundraisers in their communities around the globe including online events and facebook fundraisers.”
This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.
| Path | # | Value |
|---|---|---|
| IRS990EZ/ActivitiesNotPreviouslyRptInd | 0 | false |
| IRS990EZ/BooksInCareOfDetail/PersonNm | 0 | DAWN JUDD |
| IRS990EZ/BooksInCareOfDetail/PhoneNum | 0 | 8438646760 |
| IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt | 0 | 1166 MARINER DRIVE |
| IRS990EZ/BooksInCareOfDetail/USAddress/CityNm | 0 | CHARLESTON |
| IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd | 0 | SC |
| IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd | 0 | 29412 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt | 0 | 99408 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt | 0 | 91017 |
| IRS990EZ/ChgMadeToOrgnzngDocNotRptInd | 0 | false |
| IRS990EZ/ContributionsGiftsGrantsEtcAmt | 0 | 83212 |
| IRS990EZ/DonorAdvisedFndsInd | 0 | false |
| IRS990EZ/EngagedInExcessBenefitTransInd | 0 | false |
| IRS990EZ/ExcessOrDeficitForYearAmt | 0 | -5223 |
| IRS990EZ/FeesAndOtherPymtToIndCntrctAmt | 0 | 37913 |
| IRS990EZ/FiledScheduleAInd | 0 | true |
| IRS990EZ/ForeignFinancialAccountInd | 0 | false |
| IRS990EZ/ForeignOfficeInd | 0 | false |
| IRS990EZ/Form1120PolFiledInd | 0 | false |
| IRS990EZ/Form990TotalAssetsGrp/BOYAmt | 0 | 99408 |
| IRS990EZ/Form990TotalAssetsGrp/EOYAmt | 0 | 91017 |
| IRS990EZ/FundraisingGrossIncomeAmt | 0 | 16693 |
| IRS990EZ/GrossReceiptsAmt | 0 | 99906 |
| IRS990EZ/InfoInScheduleOPartIIIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartIIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartIInd | 0 | X |
| IRS990EZ/InvestmentIncomeAmt | 0 | 1 |
| IRS990EZ/LobbyingActivitiesInd | 0 | false |
| IRS990EZ/MadeLoansToFromOfficersInd | 0 | false |
| IRS990EZ/MethodOfAccountingAccrualInd | 0 | X |
| IRS990EZ/NetAssetsOrFundBalancesBOYAmt | 0 | 96240 |
| IRS990EZ/NetAssetsOrFundBalancesEOYAmt | 0 | 91017 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt | 0 | 96240 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt | 0 | 91017 |
| IRS990EZ/OccupancyRentUtltsAndMaintAmt | 0 | 1640 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 0 | 000.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 1 | 000.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 2 | 000.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 3 | 000.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 4 | 000.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 5 | 000.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 6 | 000.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 7 | 000.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 8 | 000.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 4 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 5 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 6 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 7 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 8 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 0 | LENNIE WOODS |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 1 | KELLY ARGRAVES PHD |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 2 | JENAE HELLER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 3 | DRU WILLIAMS |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 4 | DAWN JUDD |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 5 | DENNY WOODS |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 6 | BRUCE NEWBY |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 7 | NANETTE DETURK |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 8 | EVAN BARNES |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 0 | EXECUTIVE DI |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 1 | SCIENTIFIC D |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 2 | BOARD MEMBER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 3 | BOARD MEMBER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 4 | TREASURER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 5 | BOARD MEMBER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 6 | BOARD MEMBER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 7 | BOARD MEMBER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 8 | BOARD MEMBER |
| IRS990EZ/OperateHospitalInd | 0 | false |
| IRS990EZ/Organization501c3Ind | 0 | X |
| IRS990EZ/OrganizationDissolvedEtcInd | 0 | false |
| IRS990EZ/OrganizationHadUBIInd | 0 | false |
| IRS990EZ/OtherExpensesTotalAmt | 0 | 64944 |
| IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt | 0 | NONE |
| IRS990EZ/PartVIOfCompOfHghstPdEmplTxt | 0 | NONE |
| IRS990EZ/PoliticalCampaignActyInd | 0 | false |
| IRS990EZ/PrimaryExemptPurposeTxt | 0 | THE MISSION OF SARA'S CURE IS TO MAKE CLEAR CELL SARCOMA SURVIVABLE THROUGH EDUCATION AND SCIENTIFIC RESEARCH WHILE ENSURING ALL PATIENTS AND CAREGIVERS IMPACTED HAVE A VOICE AND PLATFORM TO ENACT CHANGE AND STRIVE TOWARDS THE CURE. |
| IRS990EZ/PrintingPublicationsPostageAmt | 0 | 632 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 0 | SARA'S CURE IS THE ONLY NON-PROFIT REPRESENTING CLEAR CELL SARCOMA IN THE USA BUT WE COLLABORATE WITH OTHERS THROUGHOUT THE WORLD TO ENSURE OUR WORK IS EFFICIENT, MEANINGFUL AND IMPACTFUL TO THE CCS FAMILY OF PATIENTS AND OUR CHAMPION CLINICIANS. THROUGHOUT 2021 WE HAVE CONTINUED FUNDING REPURPOSED DRUG TESTING BY WORKING WITH OUR MEDICAL ADVISORS AND THEIR LABS. OUR EXECUTIVE DIRECTOR SERVES ON AN FDA REPURPOSED DRUG TESTING TASK FORCE THAT MEETS MONTHLY. THIS STRATEGIC INVOLVEMENT WITH KEY LEADERS ENSURES THAT THE TIME AND MONEY SPENT IS PUT TO ITS HIGHEST AND BEST USE. IN NOVEMBER 2021 THE FIRST OF ITS KIND PHASE I/II CCS TRIAL OPENED. THIS WAS DONE IN COLLABORATION WITH RAFAEL (NOW CORNERSTONE PHARMA), THE FDA, AND MOST IMPORTANT THE CCS FAMILY OF PATIENTS. WE PARTNERED TO DO THIS BY AGREEING TO PROVIDE FINANCIAL SUPPORT TO PATIENTS IN THE FORM OF TRAVEL REIMBURSEMENT TO HELP PATIENTS GET TO TRIAL LOCATIONS. WE HIRED THE NATIONAL ORGANIZATION OF RARE DISORDERS TO MANAGE THE DISBURSEMENT OF FUNDS TO THE CCS PATIENTS DIRECTLY. WE HAVE HELPED SEVERAL PATIENTS TO DATE. THE CLINICAL TRIAL IS ONGOING. WE CONTINUE TO BUILD THE REGISTRY WITH NORD AND FINALIZED THE DATA DICTIONARY IN DEC 2021. WE CONTINUE TO SUPPORT PATIENTS THROUGH REFERRALS TO SARCOMA CENTERS OF EXCELLENCE AND TO THE DOCTORS THAT CHAMPION THE CCS RESEARCH WHO WORK WITH US TO SUPPORT OUR MISSION. WE ATTENDED THE WORLD ORPHAN DRUG CONGRESS IN AUGUST 2021 AND HAD A CCS FATHER/BOARD MEMBER ATTEND AS WELL AS OUR EXECUTIVE AND SCIENTIFIC DIRECTORS WHO ALSO ATTENDED THE NORD AND CTOS SARCOMA CONFERENCES VIRTUALLY. THE CCS FAMILY OF PATIENTS CONTINUES TO BE THE DRIVING FORCE WITHIN THE ORGANIZATION AND HAS BEEN CRITICAL TO ACTIVELY AND FINANCIALLY SUPPORTING THE WORK WE DO BY PARTICIPATING IN FOCUS GROUPS, PROVIDING PATIENT EXPERIENCE INPUT AND HOSTING FUNDRAISERS IN THEIR COMMUNITIES AROUND THE GLOBE INCLUDING ONLINE EVENTS AND FACEBOOK FUNDRAISERS. |
| IRS990EZ/ProhibitedTaxShelterTransInd | 0 | false |
| IRS990EZ/RelatedOrganizationCtrlEntInd | 0 | false |
| IRS990EZ/SchoolOperatingInd | 0 | false |
| IRS990EZ/SpecialEventsNetIncomeLossAmt | 0 | 16693 |
| IRS990EZ/StatesWhereCopyOfReturnIsFldCd | 0 | SC |
| IRS990EZ/SubjectToProxyTaxInd | 0 | false |
| IRS990EZ/SumOfTotalLiabilitiesGrp/BOYAmt | 0 | 3168 |
| IRS990EZ/TanningServicesProvidedInd | 0 | false |
| IRS990EZ/TotalExpensesAmt | 0 | 105129 |
| IRS990EZ/TotalRevenueAmt | 0 | 99906 |
| IRS990EZ/TransactionWithControlEntInd | 0 | false |
| IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd | 0 | false |
| IRS990EZ/TypeOfOrganizationCorpInd | 0 | X |
| IRS990EZ/WebsiteAddressTxt | 0 | WWW.SARASCURE.ORG |
| IRS990ScheduleA/First5Years509Ind | 0 | X |
| IRS990ScheduleA/Form990ScheduleAPartVIGrp/ExplanationTxt | 0 | OTHER 21,713 |
| IRS990ScheduleA/Form990ScheduleAPartVIGrp/FormAndLineReferenceDesc | 0 | PART III, LINE 12 |
| IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearAmt | 0 | 83212 |
| IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearMinus1YearAmt | 0 | 80588 |
| IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearMinus2YearsAmt | 0 | 97218 |
| IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearMinus3YearsAmt | 0 | 147312 |
| IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearMinus4YearsAmt | 0 | 120700 |
| IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/TotalAmt | 0 | 529030 |
| IRS990ScheduleA/GrossReceiptsAdmissionsGrp/CurrentTaxYearAmt | 0 | 16694 |
| IRS990ScheduleA/GrossReceiptsAdmissionsGrp/CurrentTaxYearMinus1YearAmt | 0 | 582 |
| IRS990ScheduleA/GrossReceiptsAdmissionsGrp/CurrentTaxYearMinus2YearsAmt | 0 | 61000 |
| IRS990ScheduleA/GrossReceiptsAdmissionsGrp/TotalAmt | 0 | 78276 |
| IRS990ScheduleA/OtherIncome509Grp/CurrentTaxYearMinus3YearsAmt | 0 | 1513 |
| IRS990ScheduleA/OtherIncome509Grp/CurrentTaxYearMinus4YearsAmt | 0 | 20200 |
| IRS990ScheduleA/OtherIncome509Grp/TotalAmt | 0 | 21713 |
| IRS990ScheduleA/PubliclySupportedOrg509a2Ind | 0 | X |
| IRS990ScheduleA/PublicSupportTotal509Amt | 0 | 607306 |
| IRS990ScheduleA/Total509Grp/CurrentTaxYearAmt | 0 | 99906 |
| IRS990ScheduleA/Total509Grp/CurrentTaxYearMinus1YearAmt | 0 | 81170 |
| IRS990ScheduleA/Total509Grp/CurrentTaxYearMinus2YearsAmt | 0 | 158218 |
| IRS990ScheduleA/Total509Grp/CurrentTaxYearMinus3YearsAmt | 0 | 147312 |
| IRS990ScheduleA/Total509Grp/CurrentTaxYearMinus4YearsAmt | 0 | 120700 |
| IRS990ScheduleA/Total509Grp/TotalAmt | 0 | 607306 |
| IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearAmt | 0 | 99906 |
| IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearMinus1YearAmt | 0 | 81170 |
| IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearMinus2YearsAmt | 0 | 158218 |
| IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearMinus3YearsAmt | 0 | 148825 |
| IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearMinus4YearsAmt | 0 | 140900 |
| IRS990ScheduleA/TotalSupportCalendarYearGrp/TotalAmt | 0 | 629019 |
| IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorNum | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine2 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt | 0 | RESTRICTED |
| IRS990ScheduleG/FundraisingEventInformationGrp/Event1Nm | 0 | SPECIAL EVENTS |
| IRS990ScheduleG/FundraisingEventInformationGrp/GrossReceiptsEvent1Amt | 0 | 16693 |
| IRS990ScheduleG/FundraisingEventInformationGrp/GrossReceiptsTotalAmt | 0 | 16693 |
| IRS990ScheduleG/FundraisingEventInformationGrp/GrossRevenueEvent1Amt | 0 | 16693 |
| IRS990ScheduleG/FundraisingEventInformationGrp/GrossRevenueTotalEventsAmt | 0 | 16693 |
| IRS990ScheduleG/FundraisingEventInformationGrp/NetIncomeSummaryAmt | 0 | 16693 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 0 | SPECIAL EVENTS OTHER EXPENSES 17,915 TAXES/LICENSES 80 ISLANDS AGAINST CANCER 7,551 EXPENSES ADVERTISING AND WEBSITE 11,794 MARKETING MATERIALS 4,239 BANK & CREDIT CARD FEES 66 SUPPLIES 1,023 TRAVEL 22,172 OTHER EXPENSES 104 TOTAL 64,944 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 1 | CREDIT CARD 3,168 0 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 2 | THE MISSION OF SARA'S CURE IS TO MAKE CLEAR CELL SARCOMA SURVIVABLE THROUGH EDUCATION AND SCIENTIFIC RESEARCH WHILE ENSURING ALL PATIENTS AND CAREGIVERS IMPACTED HAVE A VOICE AND PLATFORM TO ENACT CHANGE AND STRIVE TOWARDS THE CURE. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 3 | SARA'S CURE IS THE ONLY NON-PROFIT REPRESENTING CLEAR CELL SARCOMA IN THE USA BUT WE COLLABORATE WITH OTHERS THROUGHOUT THE WORLD TO ENSURE OUR WORK IS EFFICIENT, MEANINGFUL AND IMPACTFUL TO THE CCS FAMILY OF PATIENTS AND OUR CHAMPION CLINICIANS. THROUGHOUT 2021 WE HAVE CONTINUED FUNDING REPURPOSED DRUG TESTING BY WORKING WITH OUR MEDICAL ADVISORS AND THEIR LABS. OUR EXECUTIVE DIRECTOR SERVES ON AN FDA REPURPOSED DRUG TESTING TASK FORCE THAT MEETS MONTHLY. THIS STRATEGIC INVOLVEMENT WITH KEY LEADERS ENSURES THAT THE TIME AND MONEY SPENT IS PUT TO ITS HIGHEST AND BEST USE. IN NOVEMBER 2021 THE FIRST OF ITS KIND PHASE I/II CCS TRIAL OPENED. THIS WAS DONE IN COLLABORATION WITH RAFAEL (NOW CORNERSTONE PHARMA), THE FDA, AND MOST IMPORTANT THE CCS FAMILY OF PATIENTS. WE PARTNERED TO DO THIS BY AGREEING TO PROVIDE FINANCIAL SUPPORT TO PATIENTS IN THE FORM OF TRAVEL REIMBURSEMENT TO HELP PATIENTS GET TO TRIAL LOCATIONS. WE HIRED THE NATIONAL ORGANIZATION OF RARE DISORDERS TO MANAGE THE DISBURSEMENT OF FUNDS TO THE CCS PATIENTS DIRECTLY. WE HAVE HELPED SEVERAL PATIENTS TO DATE. THE CLINICAL TRIAL IS ONGOING. WE CONTINUE TO BUILD THE REGISTRY WITH NORD AND FINALIZED THE DATA DICTIONARY IN DEC 2021. WE CONTINUE TO SUPPORT PATIENTS THROUGH REFERRALS TO SARCOMA CENTERS OF EXCELLENCE AND TO THE DOCTORS THAT CHAMPION THE CCS RESEARCH WHO WORK WITH US TO SUPPORT OUR MISSION. WE ATTENDED THE WORLD ORPHAN DRUG CONGRESS IN AUGUST 2021 AND HAD A CCS FATHER/BOARD MEMBER ATTEND AS WELL AS OUR EXECUTIVE AND SCIENTIFIC DIRECTORS WHO ALSO ATTENDED THE NORD AND CTOS SARCOMA CONFERENCES VIRTUALLY. THE CCS FAMILY OF PATIENTS CONTINUES TO BE THE DRIVING FORCE WITHIN THE ORGANIZATION AND HAS BEEN CRITICAL TO ACTIVELY AND FINANCIALLY SUPPORTING THE WORK WE DO BY PARTICIPATING IN FOCUS GROUPS, PROVIDING PATIENT EXPERIENCE INPUT AND HOSTING FUNDRAISERS IN THEIR COMMUNITIES AROUND THE GLOBE INCLUDING ONLINE EVENTS AND FACEBOOK FUNDRAISERS. |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 0 | FORM 990-EZ, PART I, LINE 16 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 1 | FORM 990-EZ, PART II, LINE 26 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 2 | FORM 990-EZ, PART III |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 3 | FORM 990-EZ, PART III, LINE 28 |
| TransferPrsnlBnftContractsDecl/DeclarationDesc | 0 | THE ORGANIZTION DID NOT, DURING THE YEAR, RECEIVE ANY FUNDS, DORECTLY OR INDIRECTLY, TO PAY PREMIUMS ON A PERSONAL BENEFIT CONTRACT. |
| ReturnHeader/BuildTS | 0 | 2023-04-26 12:10:37Z |
| ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd | 0 | true |
| ReturnHeader/BusinessOfficerGrp/PersonNm | 0 | DAWN JUDD |
| ReturnHeader/BusinessOfficerGrp/PersonTitleTxt | 0 | TREASURER |
| ReturnHeader/BusinessOfficerGrp/PhoneNum | 0 | 8438646760 |
| ReturnHeader/BusinessOfficerGrp/SignatureDt | 0 | 2023-02-06 |
| ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt | 0 | SARA'S CURE |
| ReturnHeader/Filer/BusinessName/BusinessNameLine2Txt | 0 | CLEAR CELL SARCOMA FOUNDATION |
| ReturnHeader/Filer/BusinessNameControlTxt | 0 | SARA |
| ReturnHeader/Filer/EIN | 0 | 825445706 |
| ReturnHeader/Filer/PhoneNum | 0 | 8438646760 |
| ReturnHeader/Filer/USAddress/AddressLine1Txt | 0 | 783 STILES DRIVE |
| ReturnHeader/Filer/USAddress/CityNm | 0 | CHARLESTON |
| ReturnHeader/Filer/USAddress/StateAbbreviationCd | 0 | SC |
| ReturnHeader/Filer/USAddress/ZIPCd | 0 | 29412 |
| ReturnHeader/IRSResponsiblePrtyInfoCurrInd | 0 | false |
| ReturnHeader/PreparerFirmGrp/PreparerFirmEIN | 0 | 271340692 |
| ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt | 0 | HINSKE & CLAREY LLC |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt | 0 | 109 WAPPOO CREEK DR STE 1A |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm | 0 | CHARLESTON |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd | 0 | SC |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd | 0 | 294122166 |
| ReturnHeader/PreparerPersonGrp/PhoneNum | 0 | 8437620452 |
| ReturnHeader/PreparerPersonGrp/PreparationDt | 0 | 2024-02-06 |
| ReturnHeader/PreparerPersonGrp/PreparerPersonNm | 0 | NICHOLE V HINSKE CPA |
| ReturnHeader/ReturnTs | 0 | 2024-02-06T10:20:55-05:00 |
| ReturnHeader/ReturnTypeCd | 0 | 990EZ |
| ReturnHeader/SigningOfficerGrp/PersonFullName/PersonFirstNm | 0 | DAWN |
| ReturnHeader/SigningOfficerGrp/PersonFullName/PersonLastNm | 0 | JUDD |
| ReturnHeader/TaxPeriodBeginDt | 0 | 2022-01-01 |
| ReturnHeader/TaxPeriodEndDt | 0 | 2022-12-31 |
| ReturnHeader/TaxYr | 0 | 2022 |
No mirrored PDF or thumbnail assets are attached yet.
Displayed year
2022 • Form 990EZDetailed filing. Detailed filing data is available for this year.